Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).

Oshansky CM, Zhou J, Gao Y, Schweinle JE, Biscardi K, DeBeauchamp J, Pavetto C, Wollish A; BRITE Study Coordination Team, Webby RJ, Cioce V, Donis RO, Bright RA.

Vaccine. 2019 Jan 14;37(3):435-443. doi: 10.1016/j.vaccine.2018.11.069. Epub 2018 Dec 12.

2.

Chemical reaction vector embeddings: towards predicting drug metabolism in the human gut microbiome.

Mallory EK, Acharya A, Rensi SE, Turnbaugh PJ, Bright RA, Altman RB.

Pac Symp Biocomput. 2018;23:56-67.

3.

Knowledge gaps in therapeutic and non-therapeutic research on the Middle East respiratory syndrome.

Arabi YM, Fowler R, Bright RA, Van Kerkhove MD, Balkhy HH.

Lancet Respir Med. 2016 Feb;4(2):93-4. doi: 10.1016/S2213-2600(16)00007-2. No abstract available.

PMID:
26868624
4.

OpenFDA: an innovative platform providing access to a wealth of FDA's publicly available data.

Kass-Hout TA, Xu Z, Mohebbi M, Nelsen H, Baker A, Levine J, Johanson E, Bright RA.

J Am Med Inform Assoc. 2016 May;23(3):596-600. doi: 10.1093/jamia/ocv153. Epub 2015 Dec 7.

5.

Use of data mining at the Food and Drug Administration.

Duggirala HJ, Tonning JM, Smith E, Bright RA, Baker JD, Ball R, Bell C, Bright-Ponte SJ, Botsis T, Bouri K, Boyer M, Burkhart K, Condrey GS, Chen JJ, Chirtel S, Filice RW, Francis H, Jiang H, Levine J, Martin D, Oladipo T, O'Neill R, Palmer LA, Paredes A, Rochester G, Sholtes D, Szarfman A, Wong HL, Xu Z, Kass-Hout T.

J Am Med Inform Assoc. 2016 Mar;23(2):428-34. doi: 10.1093/jamia/ocv063. Epub 2015 Jul 23. Review.

PMID:
26209436
6.

Vaccines as a tool to estimate the burden of severe influenza in children of low-resourced areas (November 30-December 1, 2012, Les Pensieres, Veyrier-du-Lac, France).

Gessner BD, Brooks WA, Neuzil KM, Vernet G, Bright RA, Tam JS, Bresee J, Monto AS.

Vaccine. 2013 Jul 11;31(32):3222-8. doi: 10.1016/j.vaccine.2013.05.017. Epub 2013 May 22.

PMID:
23707161
7.

Antivirals in seasonal and pandemic influenza--future perspectives.

Wathen MW, Barro M, Bright RA.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:76-80. doi: 10.1111/irv.12049.

8.

PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries.

Neuzil KM, Tsvetnitsky V, Nyari LJ, Bright RA, Boslego JW; PATH's Influenza Vaccine Project team.

Expert Rev Vaccines. 2012 Aug;11(8):939-47.

PMID:
23002975
9.

United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.

Perdue ML, Bright RA.

Vaccine. 2011 Jul 1;29 Suppl 1:A48-50. doi: 10.1016/j.vaccine.2011.02.080. Review.

10.

WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14, 2008.

Bright RA, Neuzil KM, Pervikov Y, Palkonyay L.

Vaccine. 2009 Oct 23;27(45):6366-9. doi: 10.1016/j.vaccine.2009.02.084. No abstract available.

PMID:
19840675
11.

Influenza virus-like particles as pandemic vaccines.

Kang SM, Pushko P, Bright RA, Smith G, Compans RW.

Curr Top Microbiol Immunol. 2009;333:269-89. doi: 10.1007/978-3-540-92165-3_14. Review.

PMID:
19768411
12.

Influenza vaccine manufacture: keeping up with change.

Neuzil KM, Bright RA.

J Infect Dis. 2009 Sep 15;200(6):835-7. doi: 10.1086/605507. No abstract available.

PMID:
19673653
13.

A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.

Ross TM, Mahmood K, Crevar CJ, Schneider-Ohrum K, Heaton PM, Bright RA.

PLoS One. 2009 Jun 24;4(6):e6032. doi: 10.1371/journal.pone.0006032.

14.

Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method.

Deyde VM, Nguyen T, Bright RA, Balish A, Shu B, Lindstrom S, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2009 Mar;53(3):1039-47. doi: 10.1128/AAC.01446-08. Epub 2009 Jan 5.

15.

What is FDA doing about medical errors and adverse events related to medical devices?

Bright RA.

Pharmacoepidemiol Drug Saf. 2000 Sep;9(5):437-40. doi: 10.1002/1099-1557(200009/10)9:5<437::AID-PDS537>3.0.CO;2-G. No abstract available.

PMID:
19025851
16.

Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response.

Maines TR, Szretter KJ, Perrone L, Belser JA, Bright RA, Zeng H, Tumpey TM, Katz JM.

Immunol Rev. 2008 Oct;225:68-84. doi: 10.1111/j.1600-065X.2008.00690.x. Review.

PMID:
18837776
17.

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM.

Vaccine. 2008 Oct 3;26(42):5393-9. doi: 10.1016/j.vaccine.2008.07.084. Epub 2008 Aug 14.

PMID:
18706956
18.

Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92. doi: 10.1128/AAC.00555-08. Epub 2008 Jul 14.

19.

Adamantane-resistant influenza infection during the 2004-05 season.

Rahman M, Bright RA, Kieke BA, Donahue JG, Greenlee RT, Vandermause M, Balish A, Foust A, Cox NJ, Klimov AI, Shay DK, Belongia EA.

Emerg Infect Dis. 2008 Jan;14(1):173-6. doi: 10.3201/eid1401.070460.

20.

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle.

Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM.

PLoS One. 2008 Jan 30;3(1):e1501. doi: 10.1371/journal.pone.0001501.

21.

Strategy for surveillance of adverse drug events.

Bright RA.

Food Drug Law J. 2007;62(3):605-16. No abstract available.

PMID:
17915403
22.

Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide.

Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, Zhang Y, Shu Y, Gubareva LV, Cox NJ, Klimov AI.

J Infect Dis. 2007 Jul 15;196(2):249-57. Epub 2007 Jun 7.

PMID:
17570112
23.

Polygenic virulence factors involved in pathogenesis of 1997 Hong Kong H5N1 influenza viruses in mice.

Chen H, Bright RA, Subbarao K, Smith C, Cox NJ, Katz JM, Matsuoka Y.

Virus Res. 2007 Sep;128(1-2):159-63. Epub 2007 May 22.

PMID:
17521765
24.

Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.

Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, Nathan M, Smith G, Wright DC, Bright RA.

Vaccine. 2007 May 22;25(21):4283-90. Epub 2007 Mar 9.

PMID:
17403562
25.

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.

Vaccine. 2007 May 10;25(19):3871-8. Epub 2007 Feb 15.

PMID:
17337102
26.

Incidence and short-term outcomes of primary and revision hip replacement in the United States.

Zhan C, Kaczmarek R, Loyo-Berrios N, Sangl J, Bright RA.

J Bone Joint Surg Am. 2007 Mar;89(3):526-33.

PMID:
17332101
27.

Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.

Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, Bright RA, Katz JM, Mittal SK, Sambhara S.

Lancet. 2006 Feb 11;367(9509):475-81.

28.

Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States.

Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI.

JAMA. 2006 Feb 22;295(8):891-4. Epub 2006 Feb 2.

PMID:
16456087
29.

Medical device epidemiology and surveillance: patient safety is the bottom line.

Brown SL, Bright RA, Tavris DR.

Expert Rev Med Devices. 2004 Sep;1(1):1-2. Review. No abstract available.

PMID:
16293003
30.

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern.

Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ, Klimov AI.

Lancet. 2005 Oct 1;366(9492):1175-81. Epub 2005 Sep 22.

PMID:
16198766
31.

Transmission of equine influenza virus to dogs.

Crawford PC, Dubovi EJ, Castleman WL, Stephenson I, Gibbs EP, Chen L, Smith C, Hill RC, Ferro P, Pompey J, Bright RA, Medina MJ, Johnson CM, Olsen CW, Cox NJ, Klimov AI, Katz JM, Donis RO.

Science. 2005 Oct 21;310(5747):482-5. Epub 2005 Sep 26.

32.

Breast pump adverse events: reports to the food and drug administration.

Brown SL, Bright RA, Dwyer DE, Foxman B.

J Hum Lact. 2005 May;21(2):169-74.

PMID:
15886342
33.

Surveillance of medical device-related hazards and adverse events in hospitalized patients.

Samore MH, Evans RS, Lassen A, Gould P, Lloyd J, Gardner RM, Abouzelof R, Taylor C, Woodbury DA, Willy M, Bright RA.

JAMA. 2004 Jan 21;291(3):325-34.

PMID:
14734595
34.

Mechanisms of pathogenicity of influenza A (H5N1) viruses in mice.

Bright RA, Cho DS, Rowe T, Katz JM.

Avian Dis. 2003;47(3 Suppl):1131-4.

PMID:
14575128
35.

Neurological manifestations of avian influenza viruses in mammals.

Rowe T, Cho DS, Bright RA, Zitzow LA, Katz JM.

Avian Dis. 2003;47(3 Suppl):1122-6.

PMID:
14575126
36.

Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine.

Bright RA, Ross TM, Subbarao K, Robinson HL, Katz JM.

Virology. 2003 Apr 10;308(2):270-8.

37.

Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins.

Mitchell JA, Green TD, Bright RA, Ross TM.

Vaccine. 2003 Feb 14;21(9-10):902-14.

PMID:
12547601
38.

The conference on the epidemiology of medical devices in women.

Bright RA.

Epidemiology. 2002 May;13 Suppl 3:S1-9. No abstract available.

PMID:
12071475
39.

Automated support for pharmacovigilance: a proposed system.

Bright RA, Nelson RC.

Pharmacoepidemiol Drug Saf. 2002 Mar;11(2):121-5.

PMID:
11998536
40.
41.

Study design in the evaluation of breast cancer imaging technologies.

Houn F, Bright RA, Bushar HF, Croft BY, Finder CA, Gohagan JK, Jennings RJ, Keegan P, Kessler LG, Kramer BS, Martynec LO, Robinowitz M, Sacks WM, Schultz DG, Wagner RF.

Acad Radiol. 2000 Sep;7(9):684-92.

PMID:
10987329
42.

Preliminary survey of the occurrence of anaphylactoid reactions during haemodialysis.

Bright RA, Torrence ME, Daley WR, McClellan WM.

Nephrol Dial Transplant. 1999 Mar;14(3):799-800. No abstract available.

PMID:
10193851
43.

Dialysis therapy.

Bright RA.

N Engl J Med. 1998 Oct 1;339(14):1004-5. No abstract available.

PMID:
9766988
44.

Estimating the prevalence of women with breast implants.

Bright RA, Moore RM Jr.

Am J Public Health. 1996 Jun;86(6):891-2. No abstract available.

45.

Reported complications of silicone gel breast implants: an epidemiologic review.

Silverman BG, Brown SL, Bright RA, Kaczmarek RG, Arrowsmith-Lowe JB, Kessler DA.

Ann Intern Med. 1996 Apr 15;124(8):744-56. Review.

PMID:
8633836
46.

The prevalence of internal orthopedic fixation devices in children in the United States, 1988.

Moore RM Jr, Bright RA, Jeng LL, Sharkness CM, Hamburger SE, Hamilton PM.

Am J Public Health. 1993 Jul;83(7):1028-30.

47.

The prevalence of tympanostomy tubes in children in the United States, 1988.

Bright RA, Moore RM Jr, Jeng LL, Sharkness CM, Hamburger SE, Hamilton PM.

Am J Public Health. 1993 Jul;83(7):1026-8.

48.

Hyperplasia and breast cancer.

Bright RA.

Cancer Causes Control. 1993 May;4(3):289. No abstract available.

PMID:
8318645
49.

Racial differences in the prevalence of intraocular lens implants in the United States.

Sharkness CM, Hamburger S, Kaczmarek RG, Hamilton PM, Bright RA, Moore RM Jr.

Am J Ophthalmol. 1992 Dec 15;114(6):667-74.

PMID:
1463035
50.

National survey of self-reported breast implants: 1988 estimates.

Bright RA, Jeng LL, Moore RM.

J Long Term Eff Med Implants. 1993;3(1):81-9.

PMID:
10171654

Supplemental Content

Loading ...
Support Center